Phase 3 Clinical Trials With Primary Completion Dates in March 2024

This is a list of Phase 3 trials with primary completion dates in March 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2024-03-01 Phase 3 NCT03121586 Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
AVIR Atea Pharmaceuticals, Inc. 2024-03-01 Phase 3 NCT05629962 SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
BFRI Biofrontera Inc. 2024-03-01 Phase 3 NCT03573401 Study to Evaluate the Safety and Efficacy of BF-200 ALA (AmeluzĀ®) and BF-RhodoLEDĀ® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
CERE Cerevel Therapeutics Holdings, Inc. 2024-03-01 Phase 3 NCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations
DCPH Deciphera Pharmaceuticals, Inc. 2024-03-01 Phase 3 NCT05059262 Study of Vimseltinib for Tenosynovial Giant Cell Tumor
DCTH Delcath Systems, Inc. 2024-03-01 Phase 3 NCT05022901 An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
JAZZ Jazz Pharmaceuticals plc 2024-03-01 Phase 3 NCT03897127 Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
MMSI Merit Medical Systems, Inc. 2024-03-01 Phase 3 NCT03960008 Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
ONPH Oncology Pharma Inc. 2024-03-01 Phase 3 NCT02194842 Phase III Radium 223 mCRPC-PEACE III
OTLK Outlook Therapeutics, Inc. 2024-03-01 Phase 3 NCT05112861 A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders